<DOC>
	<DOCNO>NCT02286557</DOCNO>
	<brief_summary>Up 95 % individual Multiple Sclerosis report experience cognitive fatigue , characterize lack energy , feeling exhaustion , perception one unable partake daily activity . The goal project test whether methylphenidate ( MP ) , well-known psychostimulant , effective treat fatigue experience individual MS . The current study test effect MP MS fatigue clinical trial . Every participant study expose drug placebo period time . Both investigator participant unaware whether participant receive drug placebo . Upon successful completion study , physician able evaluate potential prescription MP treat fatigue person MS base solid research evidence . Importantly , MP already FDA approve widely use medication multiple clinical population .</brief_summary>
	<brief_title>Testing Effects Methylphenidate Multiple Sclerosis</brief_title>
	<detailed_description>As highlight National Clinical Advisory Board National Multiple Sclerosis Society ( NMSS ) , `` fatigue common MS ( multiple sclerosis ) symptom '' , affect 95 % individual . Higher level cognitive fatigue associate poor quality life ( Amato &amp; Portaccio , 2012 ) increase disability ( Lapierre &amp; Hum , 2007 ) , negatively affect wellness . Several medication currently prescribe individual MS suffer fatigue , amantadine modafinil . However , effect medication decrease fatigue level individual MS suboptimal ( e.g . Stankoff et al. , 2005 ) . At time , overwhelm evidence show methylphenidate effective relieve fatigue individual cancer ( Minton et al. , 2013 ) , human immunodeficiency virus ( Breitbart , Rosenfeld , Kaim , &amp; Funesti-Esch , 2001 ) , Parkinson 's disease ( Devos et al. , 2013 ) chronic fatigue syndrome ( CFS ) ( Blockmans et al. , 2006 ) . For example , individual CFS report decreased fatigue level ( measure visual analogue scale ) take MP ( Blockmans et al. , 2006 ) . Although MP demonstrate effective fatigue-relieving drug multiple clinical population discuss , effect MP MS-related fatigue objectively test . MP psychostimulant act inhibit presynaptic dopamine transporter lead suppression dopamine reuptake ( Prommer , 2012 ) . That , due reuptake suppression , dopamine remain synapsis . MP primarily affect striatum ( receive dopamine neuron projection substantia nigra par compacta ) subsequently prefrontal cortex ( PFC ) , receive dopaminergic projection striatum ( Volkow et al. , 2001 ) . To knowledge , randomize clinical trial use MP person MS assess effect medication attention , report significant improvement cognitive task performance ( PASAT ) MP treatment group ( Harel , Appleboim , Lavie , &amp; Achiron , 2009 ) compare placebo control group . While expert opinion paper sponsor NMSS recommends use MP treat fatigue ( Expert Opinion Paper , 2006 ) , knowledge , clinical trial conduce objectively test effect MP administration fatigue individual MS support recommendation . The current study fill void literature . Aim 1 : We propose test efficacy MP decrease self-reported fatigue individual MS double blind placebo control randomized clinical trial ( DBRCT ) . Aim 2 : We also examine effect MP cognitive functioning . Based exist literature MP ( Bales , Wagner , Kline , &amp; Dixon , 2009 ; Harel et al. , 2009 ) , expect MP enhance process speed attention , little impact cognitive function memory executive control . Significance : Our DBRCT first empirically assess efficacy MP treatment MS-related fatigue . The application stringent RCT methodology result Class I evidence support refute efficacy MP fatigue-relieving drug . The amelioration fatigue MS significant positive impact MS population , give prevalence negative effect fatigue .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>1 . Diagnosis Multiple Sclerosis 2 . Age : 1865 year old 1 . Participants must free : corticosteroid , currently take modafinil , amantadine psychostimulants . 2 . Participants must MS relapse free least previous 4 week . 3 . Participants consume â‰§300mg caffeine per day . 4 . Thyroid disease 5 . Anemia 6 . Decreased vitamin D .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Methylphenidate</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Cognitive Fatigue</keyword>
</DOC>